22 Mar 2016
Neuropore Therapies, Inc.
announced today that they have successfully completed the clinical conduct of their
first LGfEGNT2LhmPhase I LGfEGNT2Lhmclinical
trial. The randomized, double-blind, placebo controlled single
ascending dose study was designed to assess the safety and tolerability of
NPT200-11. A total of 55 healthy volunteers were enrolled to evaluate the
safety and tolerability of several doses of NPT200-11.
"We are very pleased with
the completion of the first clinical trial with our lead compound NPT200-11.
This is an important milestone for Neuropore and its portfolio development,”commented Dieter Meier, MD,
Neuropore’s CEO.
“The fact that NPT200-11 was well tolerated at exposures well
above those that produced robust effects in our LGfEGNT2LhmParkinson’s
disease animal models represents an essential step forward towards successful
clinical development.
We look forward to the further development of NPT200-11
as a disease modifying treatment in Parkinson’s disease.”
As announced in January 2015,
Neuropore Therapies entered into world-wide collaboration with UCB to develop
and commercialize NPT200-11 in all indications.
About Parkinson’s disease
Parkinson’s disease (PD) is the
second most common neurodegenerative disorder after Alzheimer’s disease. There
are an estimated seven to ten million patients with PD worldwide. Current
treatments for PD are effective at managing the early motor symptoms of the
disease, mainly through the use of levodopa and dopamine agonists. As the
disease progresses and dopaminergic neurons continue to be lost, these drugs
eventually become less effective at treating the symptoms. Currently there are
no approved disease modifying treatments for PD.
About NPT200-11
NPT200-11 is an orally
bioavailable small molecule, has promising drug-like properties, and has shown
robust beneficial actions on multiple endpoints in animal models.
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical
company focused on the discovery and development of innovative medicines and
solutions to transform the lives of people living with severe diseases of the
immune system or of the central nervous system. With more than 7700 people in
approximately 40 countries, the company generated revenue of € 3.9 billion in
2015. UCB is listed on Euronext Brussels (symbol: UCB)
About Neuropore Therapies, Inc.
Neuropore Therapies is developing
novel small molecule therapeutics to treat and slow the progression of
neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. The
approach being taken by Neuropore is to target an underlying pathological
process common to these disorders – the accumulation of toxic oligomeric
aggregates of misfolded neuronal proteins in cell membranes. By preventing the
formation of these toxic aggregates synaptic function may be restored and
neurodegenerative processes slowed.
Neuropore Therapies uses
structure-based drug design and dynamic molecular modeling to identify key
target regions on proteins that are important for the formation of toxic
protein aggregates. Candidate compounds targeting these regions are then
synthesized and evaluated in cell-free and cell-based assays. Promising
compounds are further evaluated in various disease-related animal models. For
more information visit www.neuropore.com.
Forward looking statements
This press release contains
forward-looking statements based on current information, projections and
assumptions of management. Statements in this press release that are not
strictly historical in nature are forward-looking statements. By their nature
forward-looking statements are not guarantees of future performance and are subject
to risks and uncertainties which may cause actual results to differ materially
from the forward-looking statements contained in this press release.
Important factors that could
result in such differences include the risks and uncertainties inherent in drug
discovery, development, approval and commercialization, collaborations with
others, and the fact that past results of clinical trials and regulatory
decisions may not be indicative of future trial results or regulatory
decisions.
Neuropore Therapies, Inc.
Dieter Meier, MD
Chief Executive Officer
+1 858-273-1831
http://www.bioportfolio.com/news/article/2653603/Neuropore-Announces-Successful-Completion-of-Phase-I-with-its-Lead-Compound-NPT200.html
No comments:
Post a Comment